Novartis is suing HRSA to impose a controversial 340B rebate model that the agency has not authorized.

News Alert

Novartis is Fifth Drugmaker to Sue HRSA to Implement Controversial 340B Rebate Model

Novartis this week became the fifth manufacturer to sue the Health Resources and Services Administration (HRSA) to implement a 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.